COMPANY

Tizona Therapeutics

HQ: South San Francisco, CA source · tizonatx.com ↗ · West Coast

Keywords: oncology TTX-080

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Jul 14, 2020 Trial start Phase 1: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers source ↗

Jun 1, 2027 (ESTIMATED) · Phase 1 · TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers · NCT04485013

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT04485013	TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	Phase 1	Active, not recruiting	Jul 14, 2020	Jun 1, 2027 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of MPM BioImpact (captured Oct 12, 2026). portfolio page ↗